The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative efficacy, safety, and tolerability of immune checkpoint inhibitors (ICIs) in cancer.
 
Laith Al-Showbaki
No Relationships to Disclose
 
Michelle Nadler
No Relationships to Disclose
 
Alexandra Desnoyers
Travel, Accommodations, Expenses - Merck
 
Fahad Almugbel
No Relationships to Disclose
 
David W. Cescon
Honoraria - Novartis; Pfizer
Consulting or Advisory Role - Agendia; AstraZeneca; Genomic Health; GlaxoSmithKline; Merck; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending - Biomarkers of TTK inhibitors (assigned to institution)
 
Eitan Amir
Honoraria - Agendia; Apobiologix; Myriad Genetics; Sandoz
Expert Testimony - Genentech/Roche